DG DISPATCH - AAN: Zonisamide effective for partial or generalized epilepsy
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AAN: Zonisamide effective for partial or generalized epilepsy

By Richard Robinson
Special to DG News

SAN DIEGO, CA -- May 4, 2000 -- Zonisamide monotherapy is effective for both partial and generalized epilepsy, according to a study presented at the 52nd Annual Meeting of the American Academy of Neurology, held here May 3, 2000.

Zonisamide is a sulfonamide drug unrelated to other current antiepileptics. Recently approved in the United States, zonisamide has been used in Japan since 1989. Kazuichi Yagi, MD, and colleagues of the University of Cincinnati in Ohio reported on post-marketing data from their study, titled, "Efficacy of zonisamide monotherapy."

The researchers treated 726 newly-diagnosed patients in Japan for a mean of 11 months with a mean dose of 249 mg/day in adults and 5.5 mg/kg/day in children.

Seizure control, defined as attaining a 50 percent or greater reduction in seizures compared to baseline, was obtained in 79 percent of 99 patients with temporal lobe epilepsy, 84 percent of 243 patients with nontemporal lobe epilepsy, and 88 percent of 17 patients with unclassified partial epilepsy. In the 367 patients with generalized seizures, zonisamide was effective in approximately two-thirds of patients.

"The Japanese data show that zonisamide consistently reduces seizure frequency by more than 50 percent," Dr. Yagi said, noting the data supports its use for both partial and generalized epilepsy.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities